Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$1.19	$1.28	$1.05 ▼ $9.58	$80.42M	-0.12	299,342 shs	100,562 shs
ENLV Enlivex Therapeutics	$1.02 -1.9%	$1.01	$0.81 ▼ $1.76	$24.12M	0.76	128,328 shs	39,279 shs
PLRX Pliant Therapeutics	$1.41 -3.4%	$1.47	$1.10 ▼ $16.52	$86.55M	1.43	1.07 million shs	551,674 shs
VTYX Ventyx Biosciences	$1.24 +6.0%	$1.22	$0.78 ▼ $5.66	$88.24M	0.73	1.28 million shs	1.29 million shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	0.00%	-3.97%	+7.08%	-27.98%	+120,999,900.00%
ENLV Enlivex Therapeutics	-0.95%	-0.95%	+14.29%	-5.45%	-33.76%
PLRX Pliant Therapeutics	+2.45%	-9.57%	+19.59%	-81.19%	-89.08%
VTYX Ventyx Biosciences	-3.32%	-15.58%	+27.38%	-32.66%	-73.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	2.641 of 5 stars	3.7	5.0	0.0	0.0	0.0	0.8	1.3
PLRX Pliant Therapeutics	4.1647 of 5 stars	4.0	2.0	0.0	4.7	2.0	1.7	0.6
VTYX Ventyx Biosciences	2.4076 of 5 stars	3.4	2.0	0.0	0.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.50	Strong Buy	$10.00	740.34% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	880.39% Upside
PLRX Pliant Therapeutics	2.00	Hold	$13.31	844.15% Upside
VTYX Ventyx Biosciences	2.75	Moderate Buy	$10.00	706.45% Upside

Current Analyst Ratings Breakdown

Latest ENLV, PLRX, CLYM, and VTYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/21/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/3/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
3/24/2025	ENLV Enlivex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00
3/18/2025	PLRX Pliant Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/4/2025	PLRX Pliant Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $1.50
3/4/2025	PLRX Pliant Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/4/2025	PLRX Pliant Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $3.00
3/4/2025	PLRX Pliant Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
3/4/2025	PLRX Pliant Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $3.00
3/4/2025	PLRX Pliant Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$10.00 ➝ $10.00
3/3/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00

(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.90 per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
PLRX Pliant Therapeutics	$1.58M	54.78	N/A	N/A	$7.91 per share	0.18
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$4.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$35.12M	-$2.13	N/A	N/A	N/A	N/A	-42.21%	-41.39%	5/21/2025 (Estimated)
ENLV Enlivex Therapeutics	-$29.07M	-$0.73	N/A	N/A	N/A	N/A	-67.57%	-58.45%	6/13/2025 (Estimated)
PLRX Pliant Therapeutics	-$161.34M	-$3.47	N/A	N/A	N/A	N/A	-48.91%	-41.09%	5/12/2025 (Estimated)
VTYX Ventyx Biosciences	-$192.96M	-$1.98	N/A	N/A	N/A	N/A	-54.94%	-50.01%	N/A

Latest ENLV, PLRX, CLYM, and VTYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CLYM Climb Bio	-$0.15	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	PLRX Pliant Therapeutics	-$0.72	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	VTYX Ventyx Biosciences	-$0.48	-$0.39	+$0.09	-$0.39	N/A	N/A
3/31/2025	Q4 2024	ENLV Enlivex Therapeutics	-$0.16	-$0.23	-$0.07	-$0.23	N/A	N/A
3/25/2025	Q4 2024	CLYM Climb Bio	-$0.15	-$0.13	+$0.02	-$0.13	N/A	N/A
3/3/2025	Q4 2024	PLRX Pliant Therapeutics	-$0.99	-$0.82	+$0.17	-$0.82	$0.08 million	N/A
2/27/2025	Q4 2024	VTYX Ventyx Biosciences	-$0.54	-$0.41	+$0.13	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	57.73	57.73
ENLV Enlivex Therapeutics	N/A	9.71	9.71
PLRX Pliant Therapeutics	0.09	10.26	10.26
VTYX Ventyx Biosciences	N/A	23.52	23.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
ENLV Enlivex Therapeutics	1.02%
PLRX Pliant Therapeutics	97.30%
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	0.80%
ENLV Enlivex Therapeutics	12.28%
PLRX Pliant Therapeutics	6.40%
VTYX Ventyx Biosciences	18.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	9	67.58 million	65.07 million	N/A
ENLV Enlivex Therapeutics	70	23.65 million	18.78 million	Optionable
PLRX Pliant Therapeutics	90	61.39 million	56.96 million	Optionable
VTYX Ventyx Biosciences	30	71.16 million	57.86 million	Optionable

ENLV, PLRX, CLYM, and VTYX Headlines

Recent News About These Companies

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

May 8 at 4:01 PM | globenewswire.com

Why Ventyx Biosciences, Inc.’s (VTYX) Stock Is Down 6.88%

May 7 at 7:19 AM | aaii.com

Ventyx Biosciences (VTYX) to Release Quarterly Earnings on Thursday

May 7 at 4:05 AM | americanbankingnews.com

Susquehanna Fundamental Investments LLC Buys Shares of 198,947 Ventyx Biosciences, Inc. (NASDAQ:VTYX)

May 6 at 4:21 AM | marketbeat.com

Great week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous year

May 4, 2025 | finance.yahoo.com

Ventyx Biosciences (VTYX) Projected to Post Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Boothbay Fund Management LLC Has $690,000 Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

May 2, 2025 | marketbeat.com

Renaissance Technologies LLC Acquires 310,800 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

April 30, 2025 | marketbeat.com

Ventyx Biosciences announces seven additional appointments to SAB

April 2, 2025 | markets.businessinsider.com

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

April 1, 2025 | globenewswire.com

Ventyx Biosciences Reports 2024 Financial Results and Progress

March 4, 2025 | tipranks.com

Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges

March 1, 2025 | tipranks.com

H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)

February 28, 2025 | markets.businessinsider.com

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

February 27, 2025 | globenewswire.com

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

February 18, 2025 | markets.businessinsider.com

Ventyx Biosciences’ VTX958 shows efficacy in Crohn’s Disease

February 18, 2025 | markets.businessinsider.com

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

February 18, 2025 | globenewswire.com

Ventyx Biosciences stock hits 52-week low at $1.57

February 12, 2025 | msn.com

Ventyx Biosciences Inc (VTYX) Stock Settles at $1.84: What’s Contributing to This Price Point?

February 5, 2025 | bovnews.com

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 5, 2025 | globenewswire.com

Why Ventyx Biosciences Inc (VTYX) Stock is Currently -1.57% Off from Its 20-Day SMA?

January 23, 2025 | bovnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, PLRX, CLYM, and VTYX Company Descriptions

Climb Bio NASDAQ:CLYM

$1.19 0.00 (0.00%)

As of 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Enlivex Therapeutics NASDAQ:ENLV

$1.02 -0.02 (-1.92%)

As of 03:45 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Pliant Therapeutics NASDAQ:PLRX

$1.41 -0.05 (-3.42%)

As of 04:00 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Ventyx Biosciences NASDAQ:VTYX

$1.24 +0.07 (+5.98%)

As of 04:00 PM Eastern

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time